The European Commission approved ravulizumab (Ultomiris) for adults with paroxysmal nocturnal hemoglobinuria.
Alexion announced Wednesday that the European Commission approved ravulizumab (Ultomiris) for adults with paroxysmal nocturnal hemoglobinuria (PNH) with hemolysis with clinical symptoms indicative of high disease activity, and also for adult patients who are clinically stable after having been treated with eculizumab (Soliris) for at least the past 6 months.
Ravulizumab, to be sold under the name Ultomiris, is Alexion's long-acting C5 complement inhibitor, and offers less frequent administration than eculizumab. It is already approved for PNH in the United States, and last month, Alexion said the FDA accepted ravulizumab for priority review for the treatment of atypical hemolytic uremic syndrome (aHUS), with a decision expected by October 2019.
“At Alexion, our goal is to continue to improve the lives of people and families affected by PNH and other serious rare diseases,” said John Orloff, MD, executive vice president and head of research and development at Alexion in a statement. “We believe Ultomiris will become the new standard of care for patients with PNH by providing immediate and complete C5 inhibition, sustained throughout the 8-week dosing interval, and reducing the number of infusions per year from 26 with Soliris to only 6 or 7 with Ultomiris. We are also particularly pleased by the positive data showing patients can successfully transition from Soliris to Ultomiris.”
The European Commission approval is based on results from 2 phase 3 studies for PNH, which can cause a wide range of debilitating symptoms and complications, including thrombosis, which can occur throughout the body, resulting in organ damage and premature death. The studies included 441 patients who either had never been treated with a complement inhibitor before or who had been stable on eculizumab. The company said the efficacy of ravulizumab administered every 8 weeks was noninferior to the efficacy of eculizumab administered every 2 weeks on all 11 endpoints. Safety profiles were similar.
With biosimilar competition to eculizumab advancing, Alexion hopes to transition most of the patients already receiving the older eculizumab onto the newer ravulizumab in the near future.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.